ACADIA PHARMACEUTICALS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $957.8M | $726.4M | $517.2M | $484.1M |
| Gross profit | — | — | $684.8M | $507.1M | $473.3M |
| Operating income | $104.8M | $230.8M | -$73.4M | -$223.6M | -$170.4M |
| Cost of revenue | $89.0M | $81.8M | $41.6M | $10.2M | $19.1M |
| Cash from operations | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M |
| Capital expenditure | $4.7M | $523,000 | $50,000 | $0 | $1.1M |
| Free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $1.6B | $1.2B | $749.0M | $587.8M | $700.1M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M |
Shares outstanding 171.2M · Free float 48.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.